Akoya BioSciences/$AKYA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Akoya BioSciences
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
Ticker
$AKYA
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
205
ISIN
US00974H1041
Website
AKYA Metrics
BasicAdvanced
$66M
-
-$0.96
1.35
-
Price and volume
Market cap
$66M
Beta
1.35
52-week high
$3.42
52-week low
$0.93
Average daily volume
816K
Financial strength
Current ratio
0.613
Quick ratio
0.363
Long term debt to equity
-68.297
Total debt to equity
-1,421.684
Interest coverage (TTM)
-3.63%
Profitability
EBITDA (TTM)
-30.011
Gross margin (TTM)
61.74%
Net profit margin (TTM)
-59.45%
Operating margin (TTM)
-46.79%
Effective tax rate (TTM)
-0.28%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
-17.49%
Return on equity (TTM)
-354.27%
Valuation
Price to revenue (TTM)
0.824
Price to book
-11.26
Price to tangible book (TTM)
-1.74
Price to free cash flow (TTM)
-2.037
Free cash flow yield (TTM)
-49.09%
Free cash flow per share (TTM)
-65.29%
Growth
Revenue change (TTM)
-14.55%
Earnings per share change (TTM)
-33.47%
3-year revenue growth (CAGR)
10.29%
3-year earnings per share growth (CAGR)
-12.63%
What the Analysts think about AKYA
Analyst ratings (Buy, Hold, Sell) for Akoya BioSciences stock.
AKYA Financial Performance
Revenues and expenses
AKYA Earnings Performance
Company profitability
AKYA News
AllArticlesVideos
Akoya Biosciences Reports First Quarter 2025 Financial Results
GlobeNewsWire·2 months ago
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
Business Wire·2 months ago
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Akoya BioSciences stock?
Akoya BioSciences (AKYA) has a market cap of $66M as of June 28, 2025.
What is the P/E ratio for Akoya BioSciences stock?
The price to earnings (P/E) ratio for Akoya BioSciences (AKYA) stock is 0 as of June 28, 2025.
Does Akoya BioSciences stock pay dividends?
No, Akoya BioSciences (AKYA) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Akoya BioSciences dividend payment date?
Akoya BioSciences (AKYA) stock does not pay dividends to its shareholders.
What is the beta indicator for Akoya BioSciences?
Akoya BioSciences (AKYA) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.